For outcome · patients with rheumatoid arthritis in adults
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
ACR 50% improvement · patients with rheumatoid arthritis in adults
Summary of findings: leflunomide + methotrexate leads to higher ACR 50 at 6 months compared with methotrexate, 6 months (high certainty).
1 finding from 1 review
HAQ change from baseline Scale from: 0 to 3. · patients with rheumatoid arthritis in adults
1 finding from 1 review
Intervention not reported
Pulmonary Methotrexate pneumonitis · patients with inflammatory arthritis on methotrexate
1 finding from 1 review
Intervention not reported
Withdrawal due to adverse events Methotrexate discontinuation · patients with inflammatory arthritis on methotrexate
1 finding from 1 review
Treatment responsea · children and young people with JIA
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Sustained clinically inactive diseasec · children and young people with JIA
Oral methotrexate plus intra‐articular glucocorticoid showed no clear difference in sustained clinically inactive diseaseb(12 months) compared with intra‐articular glucocorticoid alone (low certainty).
1 finding from 1 review
Function · children and young people with JIA
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Pain · children and young people with JIA
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Global well‐being: rated by participants · children and young people with JIA
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events(12 months) · children and young people with JIA
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Withdrawals due to adverse events · children and young people with JIA
Oral methotrexate plus intra‐articular glucocorticoid showed no clear difference in withdrawals due to adverse events(12 months) compared with intra‐articular glucocorticoid alone (low certainty).
1 finding from 1 review
OutcomesTime frame of absolute effects · children and young people with JIA
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Gastrointestinal adverse events · Patients receiving methotrexate for rheumatoid arthritis
Folic or folinic acid (any) probably leads to lower GI side effects (nausea, vomiting, abdominal pain) compared with placebo (moderate certainty).
1 finding from 1 review
Liver toxicity (incidence of transaminase elevation) · Patients receiving methotrexate for rheumatoid arthritis
Folic acid probably leads to lower liver toxicity (ie, incidence of transaminase elevation) compared with placebo (moderate certainty).
1 finding from 1 review
Haematological disorders (neutropenia, etc) · Patients receiving methotrexate for rheumatoid arthritis
Folic acid showed no clear difference in haematological disorders (incidence of neutropenia, etc) compared with placebo (low certainty).
1 finding from 1 review
Acceptability: total withdrawals · Patients receiving methotrexate for rheumatoid arthritis
Folic acid probably leads to lower total withdrawals compared with placebo (moderate certainty).
1 finding from 1 review
Number of swollen joints with folic acid (≤7 mg/wk) Change in number of swollen joints · Patients receiving methotrexate for rheumatoid arthritis
1 finding from 1 review
Number of tender joints with folic acid (≤7 mg/wk) Change in number of tender joints · Patients receiving methotrexate for rheumatoid arthritis
1 finding from 1 review
Gastrointestinal adverse events · Patients receiving methotrexate for rheumatoid arthritis
Folinic acid showed no clear difference in GI side effects (nausea, vomiting, abdominal pain) compared with placebo (moderate certainty).
1 finding from 1 review